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Fluorescent polymerase chain reaction of a panel of CA repeats on
chromosome 6 in the indolent phase of follicular centre cell lymphoma
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Summary Twenty-four cases ofhistologically defined follicle centre cell (FCC) lymphoma have been examined
for allele imbalance at 19 microsatellite loci spanning the length ofchromosome 6, including six markers within
the major histocompatibility complex (MHC), using fluorescent polymerase chain reaction (PCR) to amplify
microsatellites. Nineteen cases were observed in which imbalance of one or more markers on chromosome 6
had occurred (79%). The frequency of allele imbalance was significantly higher on 6p than 6q, and two regions
of deletions, 6p24-25 and 6p2l.3-23, were identified in which the loci showed a significantly high allele
imbalance frequency.
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Follicle centre cell lymphoma (FCC) as defined by the REAL
classification, includes centroblastic/centrocytic lymphomas
as defined by the Kiel classification, and a follicular small
cleaved, follicular mixed small- and large-cell, and follicular
predominantly large-cell lymphomas of the working formula-
tion (Harris et al., 1994). Recently, it has become apparent
that almost all cases of FCC lymphoma possess a t(14:18)
which leads to the deregulation of the bcl-2 gene (Korsmeyer,
1992). The over-expression of this gene allows the neoplastic
cell to escape the induction of apoptotic cell death, which is
the fate of many germinal centre cells. Evidence from mice
transgenic for Ig/bcl-2 has shown that lymphoproliferations,
which were initially polyclonal, eventually become clonal,
presumably because of additional genetic changes (Kors-
meyer, 1992).
The best example of how further genetic changes can
influence clinical behaviour is illustrated by the transforma-
tion of FCC lymphomas to agressive high-grade tumours. In
transgenic mice this transition is very frequently associated
with deregulation of the myc oncogene, but this is only rarely
seen in humans. In humans the most frequently seen lesions
are mutations of the p53 gene, which have been documented
in approximately 30% of cases (Sander et al., 1993).
Despite this knowledge of transformed tumours, the
nature of the events occurring in the genome early in the
natural history of the condition, during the indolent clinical
phase, is not known. A number of cytogenetic changes which
occur in addition to the t(14;18) have been identified, among
which are a number of translocations, deletions and
duplications of specific chromosomal regions (Yunis et al.,
1987). These additional changes are more frequently seen in
the tumours of higher pathological grade, according to the
working formulation (Yunis et al., 1984). One of the
consistently ocurring cytogenetic abnormalities documented,
in addition to the t(14;18), is deletion of portions of
chromosome 6. This may play an important role in
lymphoma progression (Schouten et al., 1990), as it is
seldom seen as the sole abnormality. The most common
abnormality is a partial deletion of the q arm (Offit et al.,
1993; Giadano et al., 1992), the exact frequency of which is
unknown in FCC lymphomas. A combination of cytogenetic
fluorescent in situ hybridisation (FISH), and loss of
heterozygosity (LOH) studies in non-Hodgkin's lymphomas
(NHL) have identified three minimal regions of cytogenetic
deletion (RCDs) on the long arm of chromosome 6 (Offit et
al., 1993; Menasce et al., 1994). RCD1 at 6q25-27 is
associated with intermediate-grade NHL, RCD2 at 6q21 with
high-grade NHL and RCD3 at 6q23 with low-grade
lymphomas other than FCC lymphomas. In cases of FCC
lymphomas where an abnormality of chromosome 6 was
detected in addition to the t(14;18), the deleted region was
found to cover both RCD1 and RCD3 (6q23-27) (Offit et
al., 1993). No common cytogenetic deletions of 6p or LOH
studies on 6p have been reported to date in FCC lymphoma.
The identification of loss of heterozygosity is a powerful
method for the identification of chromosomal regions which
may contain tumour-suppressor genes. We have developed a
technique which can detect allele imbalance in paraffin-
embedded material. This technique is based upon polymerase
chain reaction (PCR) amplification of microsatellites (Yandell
and Dryja, 1989), combined with fluorescent detection
(Cawkwell et al., 1993, 1994), and has a number of
advantages over autoradiographic analysis of amplified loci.
Microsatellites are highly informative and the size of the
amplified fragments is small. Small fragments such as these
can be amplified from relatively degraded DNA, obtained
from formalin-fixed paraffin-embedded pathological samples.
Fluorescent detection of microsatellites is more rapid and
also allows examination of several loci at a time. In addition,
the technique enables the accurate sizing of products and the
measurement of relative amounts of each allele present. This
allows accurate assessment of the amplified products and
determination as to whether allele imbalance has occurred
through comparison of normal and tumour tissue. Using this
technique, we have looked for evidence of allelic imbalance
with a panel of microsatellites distributed along the entire
length of chromosome 6, as a means of identifying
microscopic and submicroscopic minimally deleted regions
on chromosome 6.
Materials and methods
We have used fluorescent PCR, the methodolgy for which has
been published previously (Cawkwell et al., 1993, 1994;
Randerson et al., 1996), to amplify a series of microsatellite
markers which are distributed along the length of chromo-
some 6. In addition several markers were chosen which map
within the major histocompatibility complex (MHC) at
6p2l.3.
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Formalin-fixed paraffin-embedded material from histologi-
cally defined cases of FCC lymphoma (where it was possible
to obtain DNA from uninvolved tissue) were chosen for
study. The DNA from uninvolved tissue provides normal
somatic DNA with which to compare the tumour DNA. In
the majority of cases this was obtained from mouthwashes.
All of these cases had further sections cut, and the
histological diagnosis was reviewed and reclassified accord-
ing to the REAL classification (Harris et al., 1994).
DNA was isolated by standard sodium dodecyl sulphate
(SDS)/proteinase K phenol/chloroform extraction (Bell et al.,
1991). Paraffin-embedded sections (10 jgm) were digested for
5 days before phenol/chloroform extraction to improve yield.
Mouthwash specimens were digested overnight before an
identical extraction.
Microsatellite markers
Thirteen primer pairs located on the short arm of
chromosome 6 were chosen. Four, D6S309 located at
6p24-25, D6S277 localised to 6p24-25, D6S260 at 6pl2
(Weissenbach et al., 1992), and D6S334 at 6p2l.3-23
(Orphanos et al., 1993) were telomeric of the MHC. Six
microsatellites are located within the MHC: D6S105 located
telomeric of the HLA class 1 region at 6p2l.3 (Weber et al.,
1991); D6S276 at 6p2l.3 (Weissenbach et al., 1992); D6S265
which is closely linked to HLA-A at 6pl3.3; D6S291 at
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Figure 1 The schematic representation of chromosome 6 shows
the approximate locations of the nineteen microsatellite markers
used in the study. The bars shown next to each locus represent the
percentage frequency of allele imbalance which has been observed
at each locus individually, and for the MHC as a whole. The
highest percentage allele imbalance is seen in the regions 6p24-25
and 6p21.3 -23.
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6p2l.3 within the HLA centromeric to D6S265 (Gyapay et
al., 1994); TNFa at 6p2l.3 (Nedospadov et al., 1991); and
TAPI located within the third intron of the TAP1 gene
(Carrington and Dean, 1994). Three microsatellites, D6S248
at 6p2l, D6S260 at 6p12 (Weissenbach et al., 1992), and
D6S243 at 6qll-p21.1 (Orphanos et al., 1993) are
centromeric of the MHC.
Seven markers on 6q were also studied: D6S286 at
6pll.l-qll lies close to the centromere although whether
it is located on 6p or 6q is unclear; D6S300 at 6ql2-14;
D6S262 at 6ql6; D6S279 at 6q21-23.3; D6S290 at 6q24
(Weissenbach et al., 1992); ESR which is linked to the
oestrogen receptor gene at 6q24 (del Senno et al., 1993);
D6S264 at 6q26; and D6S281 at 6q27, close to the telomere
(Weissenbach et al., 1992). The best estimation of the
arrangement of the microsatellites in relation to each other
and their distribution along the chromosome is shown in
Figure 1.
Eight tumour-suppressor gene loci (APC x 2, p53 x 2,
DCC, WT, RBl, NM23) located on disparate chromosomes
were also examined in each case (Cawkwell et al., 1994;
Randerson et al., 1996).
Primer synthesis
Thirteen of the primer pairs were donated by J Todd,
Oxford. Primers for D6S243, D6S248, D6S334, D6S291,
D6S105, D6S265 and TAPI were synthesised in-house, on an
ABI391 DNA synthesiser (Applied Biosystems, Foster City,
CA, USA). Fluorescent primers were labelled with either, hex
amidite, 6'-fam amidite or tet amidite fluorochrome
(Cawkwell et al., 1994).
Amplification ofmicrosatellite markers
PCR was performed using an initial denaturation step of
5 min, followed by 28 or 30 cycles of 95°C for 40 s, 55°C
for 40 s and 72°C for 40 s. In the final round the extension
at 72°C was maintained for 1.5 min. All PCR amplification
was carried out in 1 xPCR buffer (10 mM Tris pH 9.1,
500 mM potassium chloride, 1.0% Triton X, 0.1% gelatin)
containing 200 jiM dNTPs. Magnesium chloride concentra-
tion was optimised for each primer pair (1.5-2 mM).
Twenty-five pmol of each primer and 1 unit of SuperTaq
Taq polymerase (HT Biotechnology, Cambridge, UK) was
used for each 25 ,ul reaction.
Analysis ofamplified product
The amplified products were visualised following electro-
phoresis on a 6% polyacrylamide denaturing gel (Severn
Biotech Ltd., Kidderminster, UK) in 1 x TBE buffer on a
model 373A automated fluorescent DNA sequencer (Applied
Biosystems). PCR product (1 pl) was combined with 4.5 pl
formamide and 0.5 ,ul of a fluorescent size marker (GS2500P,
Applied Biosystems) and denatured at 90°C for 3 min before
loading on the gel. The gel was run for 7 h at 30W and 40°C.
The laser-excited fluorescent emission of the labelled PCR
product, collected by the Genescan collection software during
the run, was automatically analysed by the Genescan analysis
program (Applied Biosystems) and used to construct a
computerised gel image, individual PCR products being
displayed as an electrophoretogram. Comparison with
internal size standards allows the exact size and the relative
quantity of a particular allele to be calculated.
Calculation of allele ratios
Using this method, allele imbalance cannot be estimated by
looking only at the tumour tissue, because the PCR
amplification will vary unpredictably and comparison has to
be made with normal uninvolved tissue. Even though PCR
amplification may vary, the ratio between the two alleles in a
heterozygous sample will remain constant. It is thereforeChromosome 6 in FCC lymphoma
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possible to compare the ratio of tumour and normal DNA
and to demonstrate allele imbalance. A 50% change in the
ratio has been taken as indicating allele imbalance (Cawkwell
et al., 1993, 1994) (Figure 2). This takes account of
infiltrating normal cells without allele imbalance and the
likelihood of less than 100% of the clonal cells carrying the
imbalance. This change can be accurately quantitated using
the fluorescent system.
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Figure 2 Electrophoretogram of the amplified microsatellite
D6S290. Allele size (in bp) is shown along the x-axis and the
quantity of fluoresence released by the PCR product is shown on
the y-axis. (a) Normal tissue gives two alleles amplified at size
254bp and 262bp (highlighted). The minor bands seen are the
representation of PCR artifacts (stutter bands) owing to the Taq
terminating 2bp prematurely. (b) DNA isolated from tumour
tissue of the same patient shows an apparent reversal in the peaks
of the two alleles. In the normal sample the ratio ofthe two allele
peak areas, N1/N2 = 1.1566, in the tumour the ratio between these
two peaks, T1/T2=0.4445. The value of TI:T2/Ni:N2=0.3843
which represents significant allelic imbalance at this locus.
Results
In order for the tumour-normal ratio (T/N) to be valid for
assigning allele imbalance, the distribution of the ratio of the
two alleles in the tumour samples (T1/T2) and the equivalent
ratios in normal tissues (NI/N2) for each individual locus
must be directly comparable. Paired t-tests comparing these
ratios demonstrated no significant differences (P<0.005) at
any of the markers in the study, showing that these
distributions were comparable. In order to determine
whether allele imbalance had occurred, on the basis of the
tumour-normal ratio alone, it was necessary to determine a
maximum value at which allele imbalance could be assigned.
The distribution of tumour-normal ratios was plotted and
was found to correspond to distributions published in
previous studies, indicating a maximum value of 0.5 for
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Figure 3 An example of a box-and-whisker plot, demonstrating
the distribution of the N1:N2 and T1:T2 ratios for locus D6S300.
Ratio values for cases which show allele imbalance at this locus
are denoted by a black circle. Both distributions have similar
median values (denoted by the heavy black line), and show no
significant asymmetry. However, the interquartile range (denoted
by the box boundaries) is extended in the tumour samples. In case
of allele imbalance the T1 :T2 ratios are found to lie at the
extremes of the distribution range (denoted by the whisker bars)
as in cases 6, 9 and 17, or to be outliers, greater than 1.5 times the
interquartile range (case 23).
Table I Allele imbalance on chromosome 6 in 24 cases of FCC lymphoma
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Loci arelistedaccording totheirrelativepositionalongthechromosome. Homozygousnon-informative loci(*); heterzygous lociwithno allele
imbalance (0); heterozygous loci with allele imbalance(0). Cases in which one or other ofthesamples could not be amplified are indicated by a
space. Loci which were not suitable forevaluation ofallele imbalance owing to microsatellite instability are denoted by a bar (I ).
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_markers with allele imbalance (Cawkwell et al., 1993;
Soloman et al., 1987). In order to visualise this further box-
and-whisker plots of the distributions of tumour and normal
ratios, for each locus, were constructed. This allowed outliers
which fell at the extremes of the distribution range or greater
than 1.5 times the interquartile range to be identified easily.
These were found to correspond to the observed cases of
allele imbalance (Figure 3).
We have looked for allele imbalance at 19 markers
located on chromosome 6 and the results are represented in
Table I. Only five of the 24 cases had no evidence of allelic
imbalance at any of the microsatellite markers. The
frequency of imbalance was found to be significantly higher
on 6p than 6q (P=0.0018). This is surprising because
cytogenetic studies have identified more frequent deletions of
6q. A Mann-Whitney-Wilcoxon comparison of the allele
imbalance frequencies obtained on 6p and 6q, with the
frequencies obtained using a panel of eight disparate
tumour-suppressor (TS) gene microsatellites on the same
sample DNA, showed that there was no significant
difference of allele imbalance between loci on 6q and the
TS gene loci (P =0.817), but that there was a significant
difference in allele imbalance between the 6p loci and the TS
gene loci (P=0.0026). This suggests that the mean allele
imbalance seen on 6q (11%) and the TS gene loci (11%)
represents the background level of allele imbalance at any
locus in FCC lymphoma. In order to map regions of allele
imbalance and possible LOH, the frequency of allele
imbalance at any one locus would need to be significantly
higher than the background imbalance, i.e. fall outside the
95% confidence intervals for the background mean (11%).
Using chi-squared tests to compare the frequency of allele
imbalance at each locus with the background mean, a
significant difference was found at seven loci on the p arm
(P<0.05). D6S309 (47%, P<0.0001) and D6S277 (30%,
P=0.0016) at 6p24-25, D6S344 (43%, P=0.0001) at
6p2l.3 -23 and D6S105 (28%, P=0.0043), D6S276 (38%,
P<0.0001), D6S265 (29%, P=0.0027) and D6S291 (25%,
P=0.0167) at 6p2l.3 within the MHC. This suggests that
the regions 6p24-25 and 6p2l.3-23 may contain sites of
genes important in the pathogenesis of FCC lymphoma.
Although no allele imbalance frequencies on 6q are
significantly higher than the background, region 6q23-25,
which shows the highest frequency of imbalance on 6q,
corresponds to the RCDs predicted from cytokinetic studies.
In individual patients it was possible to identify discrete
regions of allele imbalance using this approach. In some
instances a single region of imbalance involving several
adjacent loci was seen. In other cases several non-adjacent
loci showed imbalance, for example, case 17 where three
disparate loci, D6S277, D6S276 and D6S300, on both the p
and q arm demonstrate imbalance. Given the high incidence
of imbalance which appears to be a general feature of FCC
lymphoma, the apparent regions of imbalance may be owing
to chance. This is more likely on those cases where several
disparate loci demonstrate imbalance. In cases where several
adjacent loci are affected, the regions of imbalance generally
correspond to regions containing those loci with significantly
high frequencies of allele imbalance (6p24-25 and 6p2l.3-
23) or in the known RCDs on 6q (6q23-27).
Discussion
We have attempted to identify regions of chromosome 6
which may be important in the pathogenesis of the indolent
phase of FCC lymphoma, in addition to the deregulation of
bcl-2. The majority of cases had an abnormality of
chromosome 6. The highest frequency of allele imbalance
was observed at loci in the regions 6p24-25 and 6p2l.3-23.
These regions may represent the sites of genes which
collaborate with bcl-2 in the indolent phase. However,
6p24-25 is very close to the telomere and the high frequency
of allele imbalance may reflect this. When interpreting the
Chromosome 6 in FCC lymphoma
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results of such a study, it is of crucial importance to consider
what constitutes a significant frequency of change at a
particular locus. In colon cancer, frequencies of allele loss of
up to 70% can be seen for p53 and DCC. None of the
changes we have seen reach these levels. In transformed FCC
lymphoma, the frequency of p53 mutations of 30% is taken
as indicating a significant involvement in the transformation
process (Sander et al., 1993), and we have described a
number of loci where imbalance reaches this frequency. By
analysing the frequency of LOH at every locus, it has been
possible to identify the background rate of LOH as 11%.
With this figure it is then possible to ask the question,
whether change at any one locus differs significantly from the
mean. Using this approach a number of regions have been
identified where LOH occurs significantly more frequently
(P<0.05) (Figure 1).
We have looked carefully at the MHC (6p2l.3), a region
which has been shown to be deleted in ovarian cancer
(Foulkes et al., 1993). In these and other tumours, it has been
suggested that such deletions may allow the tumour to escape
immunosurveillance and such a mechanism could easily be
envisaged to be acting during the indolent phase of FCC
lymphoma. Four of the seven loci within the MHC showed a
significantly high frequency of allele imbalance, although in
only one case was the frequency of deletion greater than
30%. Other genes which may be involved in this region are
the tumour factor necrosis genes A and B, and the octomer
binding transcription factor OTF3. Region 6p24-25 contains
the gene for the AP-2 transcription factor and other genes of
interest in the region 6p21.3-25 include a neuroblastoma ras
viral oncogene homologue Nras3, ITPR3 the receptor for the
inositol 1,4,5-triphosphate involved in cell signalling, and
PCNAL a putative proliferating cell nuclear antigen.
Imbalance of 6q was identified at a significantly lower
frequency than on 6p, but the regions with imbalance
correspond to previously identified cytogenetic deletions.
The highest frequency of imbalance on 6q was at D6S300
(20%), but was not significantly different to the background.
The low frequency of change observed on 6q would suggest
that in FCC lymphoma, certainly during the indolent clinical
phase, this region is not pathologically important. This
reinforces the suggestion that abnormalities of 6q are
associated with lymphomas which have progressed to a
more aggressive disease.
The detection of microsatellites by polymerase chain
reaction coupled with fluorescent detection has enabled us
to look at chromosome 6 on formalin-fixed paraffin-
embedded material. This technique is more sensitive than
any of the currently available methods for carrying out LOH
studies and permits the mapping of submicroscopic regions of
imbalance in the presence ofinfiltrating normal tissue. This is
particularly important in disease where microdissection of
disease tissue is difficult. We have been able to identify two
regions of allele imbalance on chromosome 6 in cases of FCC
lymphoma, although mapping the exact boundaries of the
region has not been possible. This is owing to the fact that in
over a quarter of cases the boundary markers have been
uninformative, and that the markers involved in this study
are still a long distance apart. In order to map the extent of
the region more accurately a saturation study of more
microsatellite markers located at the boundaries of the region
is required.
We seem to have identified two regions on 6p which have
significantly higher rates of LOH than seen on the
background. The pathogenetic importance is however
difficult to ascertain. These results show that in a cell
immortalised as a result of bcl-2 deregulation, there is a
surprisingly high incidence of genetic stability. These cells are
mature, well differentiated and have few cytogenetic
abnormalities in addition to a t(14;18), which is in marked
contrast to epithelial malignancies. The nature history of
these tumours is to transform to a clinically aggressive
lymphoma in a high proportion of cases.
The finding of a high background rate of LOH is perhapsChro_mme6 in FCC Iyi.homa
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not surprising as these cells will be resistant to apoptosis as a
result of Bcl-2 expression. Random genetic lesions will not
therefore be deleted by loss of that clone as a result of
programmed cell death. These random changes will, there-
fore. continue to accumulate over the natural history of the
disease at diverse chromosome loci. When critical genes are
deleted. transformation to a high grade will occur. One such
event will be abnormalities of p53. the most common event
associated with transformation. The question may then arise
as to whether other such genes may be identified. It seems
unlikely that any single gene will be responsible for
transformation. and the reason that p53 abnormalities are
found so frequently is that rather than being directly
responsible for transformation themselves, they merely allow
the more rapid emergence of other collaborating genetic
abnormalities.
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